2024
Placenta and Intestinal Injury in Preterm Infants
Garg P, Weitkamp J, McDonald A, Cilvik S, Mir I, Shenberger J, Olaloye O, Konnikova L, Kallapur S, Garg P. Placenta and Intestinal Injury in Preterm Infants. American Journal Of Perinatology 2024, 42: 415-419. PMID: 38889889, PMCID: PMC11724007, DOI: 10.1055/a-2347-4135.Peer-Reviewed Original ResearchNecrotizing enterocolitisIntestinal injuryRisk factors associated with necrotizing enterocolitisDevelopment of necrotizing enterocolitisLow birth weight infantsAssociated with intestinal injuryExposure to inflammationProspective multi-center studyAt-risk infantsHuman clinical studiesMulti-center studyPreterm infantsPlacental pathologyPreterm birthImmunomodulatory treatmentIntrauterine environmentLaboratory predictorsCause of deathClinical outcomesClinical impactClinical studiesPostnatal lifeVulnerable infantsPost pregnancyTriggering inflammation
2023
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Otero P, Bermúdez M, Martin T, Santoro A, Yee A, Creignou M, Rodriguez C, Cerchione C, De La Rubia J, Oriol A, Waibel H, Besemer B, Thompson E, Kiesel B, Chen J, Chung A, Boss I, Gaudy A, Li S, Hsu K, Godwin C, Burgess M, San-Miguel J, Costa L. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study. Blood 2023, 142: 2011. DOI: 10.1182/blood-2023-180013.Peer-Reviewed Original ResearchRelapsed/Refractory Multiple MyelomaTreatment-emergent adverse eventsT-cell engagersLines of therapyOverall response ratePhase 1 studyTarget dosesTarget doseMedian PFSData cutoffMedian timeSafety profileCD3 T-cell engagerUpper respiratory tract infectionAnti-CD38 therapyAntitumor activityGrade 1 neurotoxicityTreatment-related deathsCytokine release syndromeRefractory multiple myelomaRespiratory tract infectionsPhase 1 trialPopulation pharmacokinetic analysisHuman clinical studiesObserved trough concentrationsP-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
Costa L, Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Boss I, Gaudy A, Hsu K, Godwin C, San-Miguel J, Wong S. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s52-s53. DOI: 10.1016/s2152-2650(23)01652-x.Peer-Reviewed Original ResearchP883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY
Wong S, Bar N, Victoria Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Aranzazu Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Chung A, Boss I, Gaudy A, LI S, Hsu K, Godwin C, Burgess M, San-Miguel J, Jose Costa L. P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY. HemaSphere 2023, 7: e1220745. PMCID: PMC10431068, DOI: 10.1097/01.hs9.0000970436.12207.45.Peer-Reviewed Original Research
2022
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong S, Bar N, Paris L, Hofmeister C, Hansson M, Santoro A, Mateos M, Rodríguez-Otero P, Lund J, Encinas C, Yee A, Oriol A, Cerchione C, de la Rubia J, Ferstl B, Carlson K, Ribas P, Bermúdez A, Boss I, Gaudy A, Li S, Hsu K, Godwin C, Burgess M, San-Miguel J, Costa L. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study. Blood 2022, 140: 400-402. DOI: 10.1182/blood-2022-159009.Peer-Reviewed Original ResearchA narrative review on the application of high-intensity focused ultrasound for the treatment of occlusive and thrombotic arterial disease
Brahmandam A, Chan SM, Dardik A, Nassiri N, Aboian E. A narrative review on the application of high-intensity focused ultrasound for the treatment of occlusive and thrombotic arterial disease. JVS Vascular Science 2022, 3: 292-305. PMID: 36276806, PMCID: PMC9579503, DOI: 10.1016/j.jvssci.2022.08.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAtherosclerotic arterial diseaseArterial diseaseEndovascular techniquesClinical studiesLow-density lipoprotein cholesterolPercutaneous endovascular techniquesThrombotic arterial diseasesAtherosclerotic plaque burdenPositive clinical outcomesAtherosclerotic plaque progressionHuman clinical studiesApplication of HIFUEnglish-language articlesEfficacy of HIFUHindlimb ischemic modelArterial recanalizationLipoprotein cholesterolThrombotic strokeClinical outcomesPlaque burdenUterine tumorsDiameter stenosisBody of evidenceIschemic modelClinical dataDorsal bed nucleus of stria terminalis in depressed and nondepressed temporal lobe epilepsy patients
Dhaher R, Bronen RA, Spencer L, Colic L, Brown F, Mian A, Sandhu M, Pittman B, Spencer D, Blumberg HP, Altalib H. Dorsal bed nucleus of stria terminalis in depressed and nondepressed temporal lobe epilepsy patients. Epilepsia 2022, 63: 2561-2570. PMID: 35883245, DOI: 10.1111/epi.17377.Peer-Reviewed Original ResearchConceptsTemporal lobe epilepsyDorsal bed nucleusTLE patientsEpilepsy patientsBed nucleusHC subjectsStria terminalisTemporal lobe epilepsy patientsMini International Neuropsychiatric InterviewMagnetic resonance imaging (MRI) scansTreatment-resistant depressionComprehensive Epilepsy CenterHealthy control subjectsStructural magnetic resonance imaging (MRI) scansResonance imaging scansNumber of patientsCase-control studyInternational Neuropsychiatric InterviewMajor depressive disorderCommon comorbid disordersHuman clinical studiesEpilepsy centersLobe epilepsyComorbid depressionControl subjects
2021
Editorial: Effects of Early Life Stress on Neurodevelopment and Health: Bridging the Gap Between Human Clinical Studies and Animal Models
Kaffman A, Herringa RJ, Sanchez MM. Editorial: Effects of Early Life Stress on Neurodevelopment and Health: Bridging the Gap Between Human Clinical Studies and Animal Models. Frontiers In Human Neuroscience 2021, 15: 751102. PMID: 34675791, PMCID: PMC8523778, DOI: 10.3389/fnhum.2021.751102.Peer-Reviewed Original Research
2020
Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions
McKnight I, Hart C, Park IH, Shim JW. Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions. Experimental Neurology 2020, 335: 113523. PMID: 33157092, PMCID: PMC7750280, DOI: 10.1016/j.expneurol.2020.113523.Peer-Reviewed Original ResearchConceptsCongenital hydrocephalusCentral nervous systemFamilial Parkinson's diseaseAlzheimer's diseaseCausative genesGenome Data ViewerHuman genetic mutationsDisease-susceptible genesHigh mutation rateGenetic mutationsHuman congenital hydrocephalusHuman clinical studiesPutative genesHuman genesGenomic informationT contentChromosomal characteristicsDNA compositionGenetic basisHigh adenineMutation rateClinical studiesGenesPreclinical modelsThymine content
2013
Stress, the HPA axis, and nonhuman primate well-being: A review
Novak MA, Hamel AF, Kelly BJ, Dettmer AM, Meyer JS. Stress, the HPA axis, and nonhuman primate well-being: A review. Applied Animal Behaviour Science 2013, 143: 135-149. PMID: 23459687, PMCID: PMC3580872, DOI: 10.1016/j.applanim.2012.10.012.Peer-Reviewed Original ResearchBaseline cortisol levelsCortisol levelsNonhuman primatesWild-living primatesHuman clinical studiesHigher cortisol levelsAltered set pointHPA axisAdrenocortical axisClinical studiesHPA systemBlood samplingCortisol concentrationsBehavioral pathologySuch monkeysNeuropsychiatric disordersStress response systemAllostatic shiftAbnormal behaviorSpontaneous developmentIndices of stressStressful eventsCortisolEarly experienceEnvironmental enrichment
2002
New horizons in AGE research
Bucala R. New horizons in AGE research. International Congress Series 2002, 1245: 113-117. DOI: 10.1016/s0531-5131(02)00886-5.Peer-Reviewed Original ResearchAdvanced glycation end productsRecent human clinical studiesGlycation end productsHuman clinical studies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply